Case stories and scientific reports
Endotoxin removal in septic E. Coli bacteremia during continuous veno-venous hemodiafiltration therapy
This clinical report of treatment with Alteco LPS Adsorber in endotoxemic septic shock from pyelonephritis, caused by the gram-negative bacteria E. Coli, shows that the treatment was safe and hemodynamic and respiratory variables improved.
Endotoxin removal therapy stabilizes critical patient with ARDS, multiple infections and septic shock
A 2-hour session of hemoperfusion with Alteco LPS Adsorber column (Alteco Medical AB, Lund, Sweden) resulted in significant decrease in endotoxin activity to 0,39 EAU. 3 hours after endotoxin adsorption treatment vasopressors were discontinued and the patient’s circulation was stable.
Effects of early use of Alteco LPS Adsorber in Acute Aortic Dissection Type A: Preliminary results
We found that early use of Alteco LPS Adsorber during CPB is safe, without lower platelet count or bleeding. Alteco LPS Adsorber reduces the levels of endotoxin resulting in peripheral lactate levels reduction and improvement of tissue perfusion.
Wroclaw, Poland: Endotoxin elimination in patients with septic shock
This study provides strong arguments for using the Alteco LPS Adsorber on patient with septic shock and endotoxemia. Reduced endotoxin activity was seen in the treatment group and a simultaneous decrease in SOFA score, vasopressor requirement as well as decreased serum lactate level.
Oulu University Hospital, Finland: A new endotoxin adsorber in septic shock
Two-hour hemoperfusion with Alteco LPS Adsorber was initiated in patients with septic shock and endotoxemia. Controls were matched for age, focus and severity of illness. Alteco LPS Adsorber treatment was associated with a decrease in noradrenaline dose, decrease in SOFA scores and LPS concentration
Studies and references
Use of an endotoxin adsorber in the treatment of severe abdominal sepsis
After LPS adsorption with Alteco LPS Adsorber, the level of LPS in the patient's bloodstream was almost eliminated: from 1.44 EU/ml before treatment to 0.03 EU/ml post treatment. The procalcitonin level and inflammatory cytokines were concurrently reduced. Also, an obvious improvement in the status of the patient's hemodynamics was seen. Forty-five days after treatment the patient is still alive. LPS adsorption may represent a significant improvement in the treatment of gram-negative sepsis and further studies are planned.
